Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a three-day pill course after joint replacement speed up recovery?

NCT ID NCT07685743

Not yet recruiting Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This trial tests whether taking the anti-bleeding medication tranexamic acid (TXA) for three days after hip or knee replacement surgery helps people recover faster and with less pain. Adults with osteoarthritis who are having a first-time joint replacement receive either TXA or a placebo pill on days 1, 2, and 3 after surgery, in addition to standard TXA given before the incision. Researchers measure joint function, pain, and range of motion at 2, 6, and 12 weeks after surgery to see if the extended TXA regimen improves outcomes without raising complication risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tranexamic acid (TXA)
What this could lead to
If it works, this could lead to a simple, low-cost way to improve recovery and reduce blood loss after joint replacement surgery.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. TXA can rarely cause blood clots or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) OF THE HIP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, hip osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOARTHRITIS (OA) OF THE HIP OSTEOARTHRITIS (OA) OF THE KNEE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.